Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $8.00.

Several brokerages have recently commented on QNCX. Wall Street Zen cut Quince Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Oppenheimer began coverage on Quince Therapeutics in a research report on Monday, March 24th. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, D. Boral Capital reiterated a “buy” rating and set a $4.00 price target on shares of Quince Therapeutics in a research report on Friday, June 13th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ieq Capital LLC acquired a new position in shares of Quince Therapeutics in the first quarter valued at approximately $1,073,000. Shay Capital LLC boosted its position in Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after acquiring an additional 104,616 shares during the last quarter. Intellectus Partners LLC acquired a new position in Quince Therapeutics during the 1st quarter worth approximately $71,000. Geode Capital Management LLC boosted its holdings in Quince Therapeutics by 10.9% during the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after purchasing an additional 36,807 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Quince Therapeutics during the fourth quarter worth $57,000. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Trading Up 10.3%

Shares of Quince Therapeutics stock opened at $1.60 on Thursday. The company’s fifty day moving average price is $1.12 and its two-hundred day moving average price is $1.39. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The firm has a market capitalization of $72.75 million, a PE ratio of -1.15 and a beta of 0.80. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.05 and a quick ratio of 4.05.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, analysts expect that Quince Therapeutics will post -1.21 EPS for the current year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.